Cancer Family
Lipomatous Neoplasm
CI-CAN-00000216Explore in graph →
Non-malignant55 active trials1 approved drugs9 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000216Explore in graph →
Clinical trials
155 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05496569 | TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma | terminated | Phase 2 | 26 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Nov 21, 2025 | clinicaltrials |
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | terminated | Phase 1 | 11 | Numab Therapeutics AGINDUSTRY | 1 | Jul 23, 2025 | clinicaltrials |
| NCT05580588 |
| Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas |
| terminated |
| Phase 2 |
| 14 |
| Shanghai Pharma Biotherapeutics USA Inc.INDUSTRY |
| 1 |
| Jun 13, 2025 |
| clinicaltrials |
| NCT04213794 | Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients(TOASTIT) | terminated | Early Phase 1 | 2 | Mayo ClinicOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT04979442 | Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma(MANTRA) | terminated | Phase 3 | 175 | Rain Oncology IncINDUSTRY | 15 | Jan 14, 2025 | clinicaltrials |
| NCT03604783 | Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors | terminated | Phase 1 | 74 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03670069 | Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas | terminated | Phase 1 | 27 | Fred Hutchinson Cancer CenterOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT05116683 | ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma(ATX-101) | terminated | Phase 2 | 4 | Benjamin IzarOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT03399448 | NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) | terminated | Phase 1 | 3 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03959033 | Patient Reported Outcome Measures (PROMs) With Trabectedin | terminated | — | 7 | University of LeedsOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT03074318 | Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery | terminated | Phase 1 / Phase 2 | 35 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT01876043 | Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial(APLIPO) | terminated | Phase 2 | 24 | Institut BergoniéOTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT02609984 | Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002) | terminated | Phase 2 | 89 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jul 7, 2020 | clinicaltrials |
| NCT01957709 | Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma | terminated | Early Phase 1 | 8 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 10, 2019 | clinicaltrials |
| NCT00233948 | Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma | terminated | Phase 1 / Phase 2 | 29 | City of Hope Medical CenterOTHER | 1 | Apr 1, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Nov 21, 2025source: clinicaltrials